Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.76B 2.36B 2.2B 2.02B 3.8B 264B 3.87B 26.14B 10.19B 132B 10.36B 10.13B 438B P/E 2026 *
-237x
P/E 2027 * 38.7x
Enterprise Value 2.76B 2.36B 2.2B 2.02B 3.8B 264B 3.87B 26.14B 10.19B 132B 10.36B 10.13B 438B EV / Sales 2026 *
3.11x
EV / Sales 2027 * 2.01x
Free-Float
95.51%
Yield 2026 *
-
Yield 2027 * -
1 day-2.25%
1 week+0.64%
Current month+6.32%
1 month+0.06%
3 months-2.55%
6 months-6.70%
Current year-4.53%
1 week 46.93
Extreme 46.93
49.82
1 month 42.62
Extreme 42.625
52.5
Current year 42.45
Extreme 42.45
59.68
1 year 42.45
Extreme 42.45
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 21/12/2005
Director of Finance/CFO 67 22/08/2021
Compliance Officer 63 31/12/2011
Director TitleAgeSince
Director/Board Member 64 21/12/2005
Chairman 81 09/08/2016
Director/Board Member 80 15/11/2010
Date Insider Type Main position Quantity % Market Cap.
12/08/26 Fiscal year

Chief Technology Officer

4,097 0.0073%
12/08/26 Fiscal year

Chief Financial Officer

3,104 0.0055%
12/08/26 Fiscal year

Founder

72,340 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%+0.64%+11.18%+53.21% 2.76B
-2.11%+9.92%+75.99%+36.44% 368B
-0.45%+0.70%+24.21%-13.11% 70.1B
-1.39%+5.41%+49.19%+145.31% 12.04B
-1.85%-0.12%-2.05%-0.25% 8.66B
+1.41%-1.26%-10.82%0.00% 4.86B
+4.77%+1.09%-26.39%+19.47% 4.46B
+8.85%-18.65%-15.25%+23.50% 3.48B
+1.95%-2.83%-8.04%-4.20% 2.17B
+3.78%-3.91%-22.29%+36.76% 1.97B
Average +1.51%-0.78%+7.57%+29.71% 47.81B
Weighted average by Cap. +0.26%+7.46%+62.64%+30.54%

Financials

2026 *2027 *
Net sales 886M 758M 708M 649M 1.22B 84.76B 1.24B 8.39B 3.27B 42.48B 3.33B 3.25B 141B 1.37B 1.17B 1.1B 1.01B 1.89B 131B 1.93B 13B 5.07B 65.77B 5.15B 5.04B 218B
Net income -11.54M -9.88M -9.22M -8.46M -15.9M -1.1B -16.21M -109M -42.65M -554M -43.35M -42.4M -1.83B 71.54M 61.25M 57.15M 52.44M 98.54M 6.85B 100M 678M 264M 3.43B 269M 263M 11.36B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
20/08/26 US$47.45 -2.25% 646,851
19/08/26 US$48.54 -1.00% 797,223
18/08/26 US$49.03 +1.57% 592,240
17/08/26 US$48.27 0.00% 536,730
14/08/26 US$48.27 +2.38% 331,731
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
47.45USD
Average target price
61.75USD
Spread / Average Target
+30.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock